BR112013002096A2 - compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas - Google Patents
compostos de agonistas de receptor glp-1 possuindo regiões estabilizadasInfo
- Publication number
- BR112013002096A2 BR112013002096A2 BR112013002096A BR112013002096A BR112013002096A2 BR 112013002096 A2 BR112013002096 A2 BR 112013002096A2 BR 112013002096 A BR112013002096 A BR 112013002096A BR 112013002096 A BR112013002096 A BR 112013002096A BR 112013002096 A2 BR112013002096 A2 BR 112013002096A2
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- receptor agonist
- agonist compounds
- stabilized regions
- stabilized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36852210P | 2010-07-28 | 2010-07-28 | |
| PCT/US2011/045614 WO2012015975A2 (en) | 2010-07-28 | 2011-07-27 | Glp-1 receptor agonist compounds having stabilized regions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013002096A2 true BR112013002096A2 (pt) | 2019-09-24 |
Family
ID=45530699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013002096A BR112013002096A2 (pt) | 2010-07-28 | 2011-07-27 | compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9217022B2 (pt) |
| EP (1) | EP2598161A4 (pt) |
| JP (1) | JP2013535471A (pt) |
| KR (1) | KR20130101005A (pt) |
| CN (1) | CN103200956A (pt) |
| AU (1) | AU2011282745A1 (pt) |
| BR (1) | BR112013002096A2 (pt) |
| CA (1) | CA2806749A1 (pt) |
| EA (1) | EA201390182A1 (pt) |
| MX (1) | MX2013001131A (pt) |
| WO (1) | WO2012015975A2 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| BR112015014510A2 (pt) | 2012-12-21 | 2017-11-21 | Sanofi Sa | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| US20070238669A1 (en) * | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
| US7816324B2 (en) * | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| US8236983B2 (en) | 2008-03-13 | 2012-08-07 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by apoptosis |
| ES2430067T3 (es) * | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
| JP2012505637A (ja) * | 2008-10-15 | 2012-03-08 | アンジオケム，インコーポレーテッド | Ｇｌｐ−１アゴニストのコンジュゲート及びその使用 |
| EP2413955A4 (en) * | 2009-04-01 | 2012-12-26 | Amylin Pharmaceuticals Inc | AGONIST COMPOUNDS OF GLP-1 RECEPTORS HAVING CONFORMATIONAL CONSTRAINTS AT THEIR N-TERMINAL END |
| US9296805B2 (en) | 2009-06-18 | 2016-03-29 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
-
2011
- 2011-07-27 CN CN2011800465658A patent/CN103200956A/zh active Pending
- 2011-07-27 AU AU2011282745A patent/AU2011282745A1/en not_active Abandoned
- 2011-07-27 US US13/812,445 patent/US9217022B2/en not_active Expired - Fee Related
- 2011-07-27 JP JP2013521955A patent/JP2013535471A/ja active Pending
- 2011-07-27 CA CA2806749A patent/CA2806749A1/en not_active Abandoned
- 2011-07-27 KR KR1020137005452A patent/KR20130101005A/ko not_active Application Discontinuation
- 2011-07-27 MX MX2013001131A patent/MX2013001131A/es unknown
- 2011-07-27 WO PCT/US2011/045614 patent/WO2012015975A2/en active Application Filing
- 2011-07-27 EP EP11813145.7A patent/EP2598161A4/en not_active Withdrawn
- 2011-07-27 EA EA201390182A patent/EA201390182A1/ru unknown
- 2011-07-27 BR BR112013002096A patent/BR112013002096A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2598161A2 (en) | 2013-06-05 |
| AU2011282745A1 (en) | 2013-03-14 |
| MX2013001131A (es) | 2013-10-17 |
| KR20130101005A (ko) | 2013-09-12 |
| CN103200956A (zh) | 2013-07-10 |
| EP2598161A4 (en) | 2014-02-19 |
| WO2012015975A2 (en) | 2012-02-02 |
| US9217022B2 (en) | 2015-12-22 |
| US20130184203A1 (en) | 2013-07-18 |
| JP2013535471A (ja) | 2013-09-12 |
| CA2806749A1 (en) | 2012-02-02 |
| EA201390182A1 (ru) | 2014-01-30 |
| WO2012015975A3 (en) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2379069I2 (lt) | S1p receptoriaus agonisto dozavimas | |
| CY2020010I1 (el) | Ενωσεις oi οποιες τροποποιουν τον υποδοχεα ανδρογονου | |
| BR112013002096A2 (pt) | compostos de agonistas de receptor glp-1 possuindo regiões estabilizadas | |
| LT2593452T (lt) | Heterocikliniai junginiai, kaip ip receptoriaus agonistai | |
| BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
| BRPI1015096A2 (pt) | agonista de receptor beta de hormônio tireoideano | |
| BR112013009935C8 (pt) | compostos | |
| DK2794626T6 (da) | E-selectin-antagonistforbindelser | |
| BR112013003753A2 (pt) | compostos | |
| BR112012006859A2 (pt) | compostos | |
| DK2427449T3 (da) | Vinylindazolylforbindelser | |
| DK2821407T3 (da) | Piperidinoncarboxamidazaindan-cgrp receptorantagonister | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| DK2648516T3 (da) | Substituerede pyridinon-pyridinylforbindelser | |
| DK2501703T3 (da) | Spiropiperidinforbindelser som orl-1-receptorantagonister | |
| EP2427430A4 (en) | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | |
| CO6801726A2 (es) | Compuestos | |
| DK2501704T3 (da) | Spiropiperidinforbindelser som oral-1-receptorantagonister | |
| DK2649070T3 (da) | Triazolpyridinforbindelser | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| BR112012002336A2 (pt) | compostos aza-heterocíclicos | |
| BR112014010780A2 (pt) | conjugados do peptídeo agonista do receptor glp-1-gastrina | |
| HK1192228A1 (zh) | 受體拮抗劑 | |
| BR112012002824A2 (pt) | agonistas de receptor de esfingosina-1-fosfato | |
| DK2539323T3 (da) | Fobindelser som Bradykinin-B1-antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |